Dear Friends and Colleagues,
Welcome to the new edition of the IMS Post!
Once again, thanks to the generosity and support of the Paula and Rodger Riney Foundation, IMS led the way in funding opportunities in multiple myeloma, distributing $3.42 million in grants. This year, we have funded 12 Translational Research Awards, and 5 Career Development Awards. This represents developing relationships with 22 institutions in 10 countries. IMS continues to develop focus and interest in promoting research by providing funding with eye on translation to patient care and promoting career of young scientist to become myeloma researcher.
Whether in-person or virtual, we are looking forward to welcoming many of you to the 4th Immune Effector Cell meeting in Boston MA. If you have not yet already, there is still time to register as a virtual attendee!
This year promises to be the biggest IMS Annual Meeting yet! The 20th Annual IMS Meeting will take place in Athens, Greece, on September 27-30, 2023. We are accepting abstracts until May 30. Please keep an eye out for emails related to registration, abstract submission and more. We are looking forward to reading your abstracts, please encourage your colleagues to submit as well. More details can be found on the meeting website.
There is more in store for IMS in the near future including our therapeutic Map (TMap) program, the IMS clinical studies summit and plans for IMS data hub. So please continue to check our website for more updates. If you have any questions about our activities, membership, or any ideas for future issues, please reach out to Moira Hancock.
Nikhil Munshi, MD
